MiNK Therapeutics (INKT) Accounts Payables (2020 - 2026)
MiNK Therapeutics (INKT) posted Accounts Payables of $3.4 million for Q1 2026, down 0.99% sequentially from $3.4 million in Q4 2025, and up 27.44% YoY from $2.7 million in Q1 2025.
MiNK Therapeutics (INKT) Accounts Payables (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Accounts Payables for 7 years, with the latest figure at $3.4 million in Q1 2026.
- Quarterly Accounts Payables rose 27.44% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 27.44% YoY) and the FY2025 annual result came in at $3.4 million, up 25.55% from the prior year.
- Accounts Payables fell to $3.4 million in Q1 2026 per INKT's latest filing, from $3.4 million in the prior quarter.
- Over five years, Accounts Payables peaked at $6.0 million in Q1 2023 and troughed at $2.4 million in Q3 2024.
- A 5-year average of $3.9 million and a median of $3.7 million in 2025 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables jumped 213.78% in 2022, then sank 44.84% in 2024.
- Over 5 years, Accounts Payables stood at $5.8 million in 2022, then sank by 32.82% to $3.9 million in 2023, then plunged by 30.26% to $2.7 million in 2024, then advanced by 25.55% to $3.4 million in 2025, then fell by 0.99% to $3.4 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $3.4 million, $3.4 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - | 3.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.92 Mn |
| Mar 31, 2026 | 3.39 Mn |
| Dec 31, 2025 | 3.43 Mn |
| Sep 30, 2025 | 3.69 Mn |
| Jun 30, 2025 | 3.31 Mn |
| Mar 31, 2025 | 2.66 Mn |
| Dec 31, 2024 | 2.73 Mn |
| Sep 30, 2024 | 2.36 Mn |
| Jun 30, 2024 | 3.20 Mn |
| Mar 31, 2024 | 3.49 Mn |
| Dec 31, 2023 | 3.91 Mn |
| Sep 30, 2023 | 4.28 Mn |
| Jun 30, 2023 | 4.89 Mn |
| Mar 31, 2023 | 6.00 Mn |
| Dec 31, 2022 | 5.82 Mn |
| Sep 30, 2022 | 5.17 Mn |
| Jun 30, 2022 | 4.79 Mn |
| Mar 31, 2022 | 3.73 Mn |
| Dec 31, 2021 | 3.00 Mn |
| Sep 30, 2021 | 1.65 Mn |